ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "quality of life"

  • Abstract Number: 1921 • ACR Convergence 2022

    Association Between Knee Osteoarthritis and Health-Related Quality of Life in Persons with Type 2 Diabetes

    Lauren King1, Esther Waugh1, Ian Stanaitis2, Alanna Weisman1, Baiju Shah1, Lorraine Lipscombe1 and Gillian Hawker1, 1University of Toronto, Toronto, ON, Canada, 2Women's College Hospital, Toronto, ON, Canada

    Background/Purpose: Knee osteoarthritis (OA) and type 2 diabetes commonly co-occur due to shared risk factors. Both knee OA and type 2 diabetes negatively impact health-related…
  • Abstract Number: 0208 • ACR Convergence 2022

    Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and Associated Patient-Reported Outcomes and Biomarkers in a Phase 2 Clinical Trial in Dermatomyositis (DM)

    Josh Dan1, Jay Patel2, Grant Sprow3, DeAnna Diaz4, Nilesh Kodali5, Rui Feng6, Barbara White7 and Victoria Werth8, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 2Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, 3Albert Einstein College of Medicine, Philadelphia, PA, 4Philadelphia College of Medicine, Philadelphia, PA, 5New Jersey Medical School, Coppell, TX, 6University of Pennsylvania, Philadelphia, 7SFJ Pharmaceuticals, Towson, MD, 8University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Background/Purpose: Retrospective reviews of clinical databases from two sites have identified strong relationships between patient-reported outcomes and skin activity in DM, as measured by CDASI-A.…
  • Abstract Number: 1050 • ACR Convergence 2022

    Clinically Recognized Depression and Mental Health Treatment in a Single Center Cohort of Patients with Systemic Sclerosis

    Marissa Savoie1, Alexandra Poeschla1, na lu2, Yuqing Zhang3, Marcy Bolster1, Sara Schoenfeld1 and Flavia Castelino1, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Boston, MA, 3Massachusetts General Hospital, Quincy, MA

    Background/Purpose: The prevalence of depression among patients with systemic sclerosis (SSc) is 35-65%1, yet little is known about mental health care utilization in SSc. It…
  • Abstract Number: 1973 • ACR Convergence 2022

    Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis

    Burcu Aydemir1, Jing Song2, Lutfiyya Muhammad3, Daniela Grimaldi1, Kathryn Reid1, Phyllis Zee1, Rowland Chang4 and Yvonne Lee1, 1Northwestern University, Chicago, IL, 2Northwestern University, Evanston, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Northwestern University Division of Rheumatology, Chicago, IL

    Background/Purpose: Despite treatment with strong immunosuppressive medications, more than half of patients with rheumatoid arthritis (RA) still report pain. Pain can spread from joint sites…
  • Abstract Number: 0285 • ACR Convergence 2022

    Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting

    Roberto Felice Caporali1, Jayeshkumar Patel2, Oliver Howell3, sander strengholt4, Hannah Jones3 and Peter Taylor5, 1University of Milan, Milano, Italy, 2AbbVie, Inc., North Chicago, IL, 3Adelphi Real World, Bollington, United Kingdom, 4AbbVie, Inc., Abcoude, Netherlands, 5University of Oxford, Oxford, United Kingdom

    Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor, is a newly approved advanced therapy for patients (pts) with rheumatoid arthritis (RA), thus real-world evidence is lacking.…
  • Abstract Number: 1299 • ACR Convergence 2022

    Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children

    Jo-Anne Marcuz1, Brian Feldman2, Y. Ingrid Goh3, Niina Kim4, Piya Lahiry5, Deborah Levy2, Elizaveta Limenis6, Jeanine McColl7, Christine O'Brien8, Susan Paetkau4, Shirley Tse2, Kristi Whitney8 and Ronald Laxer2, 1Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, 2Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, 4The Hospital for Sick Children, Toronto, ON, Canada, 5Division of Rheumatology, The Hospital for Sick Children; Department of Pediatrics, University of Toronto, Toronto, ON, Canada, 6Division of Rheumatology, The Hospital for Sick Children; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 7Division of Rheumatology, The Hospital for Sick Children; University of Toronto, Toronto, ON, Canada, 8Division of Rheumatology and Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children with significant morbidity that extends into adulthood. Despite advances in effective…
  • Abstract Number: 2066 • ACR Convergence 2022

    Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population

    Daniela Marengo-Rodriguez1, Astrid Hernandez-De La Torre1, Maria Jose Chavez-Barajas1, André Fortanell-Meza2, Ana Barrera-Vargas2, Diego San Agustin-Morales2 and Javier Merayo-Chalico3, 1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 3Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico

    Background/Purpose: Patients with SLE present with greater sexual dysfunction (SxD) than patients with other chronic diseases [1]. These patients tend to be younger compared to…
  • Abstract Number: 0390 • ACR Convergence 2022

    Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients

    Sonia Pastor Navarro1, Marta Ibáñez Martínez1, Olga Compán Fernández1, Belén Miguel Ibáñez1, Olga Martínez González1, Cristina Hidalgo Calleja1, Ana Isabel Turrión Nieves1, Susana Gómez Castro2 and Carlos Montilla Morales1, 1Hospital Universitario de Salamanca, Salamanca, Spain, 2Hospital Universitario Salamanca, Salamanca, Spain

    Background/Purpose: Symptomatic onset long after recovery from the acute phase of COVID-19 infection has been reported by the population. Currently, it is not known how…
  • Abstract Number: 1336 • ACR Convergence 2022

    Productivity Analysis in Patients with Idiopathic Inflammatory Myopathies and Relationship with Quality of Life and Emotional Domain: Preliminary Data from a Monocentric Cohort

    Chiara Cardelli1, Michele Diomedi1, Simone Barsotti1, Alessandra Tripoli2, Linda Carli1 and Marta Mosca1, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Vecchiano, Italy

    Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are chronic diseases often causing disability in patients, associated with both disease activity and damage accrual. These conditions might reduce…
  • Abstract Number: 2070 • ACR Convergence 2022

    Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis

    Sarah Dyball1, John Reynolds2, Hector Chinoy3, Ariane Herrick1, Sahena Haque4, Ellen Bruce5, Sophia Naz6, Ben Parker7 and Ian N. Bruce8, 1The University of Manchester, Manchester, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3The University of Manchester, Sale, United Kingdom, 4Manchester Foundation Trust, Manchester, United Kingdom, 5Kellgren Centre for Rheumatology, Manchester, United Kingdom, 6Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, 7Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 8Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Poor health-related quality of life (HR-QoL) is well recognised within patients with connective tissue diseases (CTD). We hypothesised that subgroups of patients across the…
  • Abstract Number: 0395 • ACR Convergence 2022

    How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study

    Uta Kiltz1, Jan Brandt-Juergens2, Peter Kästner3, Elke Riechers4, Daniel Peterlik5, Christina Budden5 and Hans-Peter Tony6, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumatologische Schwerpunktpraxis, Berlin, Germany, 3Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, 4Medizinische Hochschule Hannover, Hannover, Germany, 5Novartis Pharma GmbH, Nürnberg, Germany, 6Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany

    Background/Purpose: There is a higher prevalence of obesity in patients (pts) with psoriatic disease1. The German non-interventional study AQUILA provides real-world data on the influence…
  • Abstract Number: 1344 • ACR Convergence 2022

    Patient-reported Outcomes in Lupus Low Disease Activity State: Impact of Fatigue

    Rodrigo De Moura Rodrigues, Alexandre Moura dos Santos, Daniel Sampaio Cardoso, Emily Figueiredo Neves Yuki, Danieli Castro Oliveira de Andrade, Sandra Gofinet Pasoto, Eduardo Ferreira Borba Neto, Eloisa Silva Dutra de Oliveira Bonfa and Luciana Seguro, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Patient Reported Outcomes (PROs) can be assessed by self-administered questionnaires and can lead to better decision-making by physicians. The aim of this study was…
  • Abstract Number: 2094 • ACR Convergence 2022

    Predictors of Health-Related Quality of Life (HRQoL) in Adults with Juvenile- and Adult-onset Systemic Lupus Erythematosus: Results from a Multiethnic US Cohort (LUMINA)

    R. Ezequiel Borgia1, Manuel Ugarte-Gil2, Luis Vilá3, John Reveille4, Gerald McGwin5 and Graciela Alarcón6, 1UH Rainbow Babies & Children's Hospital, Cleveland, OH, 2Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3University of Puerto Rico Medical Sciences Campus, San Juan, PR, 4University of Texas McGovern Medical School, Houston, TX, 5Department of Epidemiology, School of Public Health, The University of Alabama at Birmingham, Birmingham, AL, 6The University of Alabama at Birmingham, Oakland

    Background/Purpose: To examine and compare baseline predictors of improvement in HRQoL in adults with systemic lupus erythematosus (SLE) with disease onset occurring before age 24…
  • Abstract Number: 0409 • ACR Convergence 2022

    Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies

    Philip J Mease1, Atul Deodhar2, Maxime Dougados3, Maureen Dubreuil4, Marina Magrey5, Helena Marzo-Ortega6, Martin Rudwaleit7, Christine de la Loge8, Alicia Ellis9, Carmen Fleurinck10, Marga Oortgiesen11, Vanessa Taieb12 and Lianne Gensler13, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Oregon Health & Science University, Portland, OR, USA, Portland, OR, 3Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, 4Department of Rheumatology, Boston University School of Medicine, Boston, MA, 5Case Western Reserve University, University Hospitals, Richfield, OH, 6Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, 7University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 8UCB Pharma, Brussels, Belgium, 9UCB Pharma, Raleigh, 10UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, 11UCB Pharma, Raleigh, NC, 12UCB Pharma, Colombes, France, 13Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ improved signs and symptoms and reduced disease activity…
  • Abstract Number: 1345 • ACR Convergence 2022

    Is Perceived Stress Associated with COVID-19 or Having a Systemic Rheumatic Disease?

    Jonah Levine, Medha Barbhaiya, Vivian Bykerk, Deanna Jannat-Khah, DrPH, MSPH and Lisa Mandl, Hospital for Special Surgery, New York, NY

    Background/Purpose: The SARS-CoV-2 pandemic is a worldwide mental health crisis. We evaluated perceived stress in patients seeking care for musculoskeletal conditions, and explored associations with…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology